Marker Therapeutics, Inc.: management transactions · United States · SEC (Form 4)

About Marker Therapeutics, Inc.

Marker Therapeutics, Inc. is a U.S.-based biotechnology company listed on the Nasdaq Stock Market in the United States (United States), focused on immuno-oncology and next-generation T cell therapies. It is best characterized as a clinical-stage, pre-revenue company whose investment profile is driven by pipeline optionality, clinical execution, and financing capacity rather than commercial sales. The company is headquartered in Houston, Texas, and maintains deep scientific and operational links to the Texas Medical Center and Baylor College of Medicine, where its core technology originated.([sec.gov](https://www.sec.gov/Archives/edgar/data/1094038/000110465925111502/mrkr-20250930x10q.htm?utm_source=openai)) Marker’s corporate roots go back to Marker Therapeutics, LLC, formed in December 2015 by John Wilson together with members of the Baylor College of Medicine research team to license and advance technology developed at Baylor. The company later became Marker Therapeutics, Inc. through a 2018 merger transaction and has continued to present itself as an academic-origin platform company. Its scientific identity centers on MAR-T cell therapy, a non-genetically engineered approach that uses T cells designed to recognize multiple tumor antigens, which the company argues may provide a broader and potentially more durable anti-tumor response than single-target approaches.([ir.markertherapeutics.com](https://ir.markertherapeutics.com/static-files/5e90a8f8-754a-4f28-9fa9-79db0fed5a85?utm_source=openai)) From an operating perspective, Marker is primarily developing cell-based immunotherapies for hematologic malignancies and selected solid tumors. Its lead candidate, MT-601, is being evaluated in a Phase 1 study in lymphoma patients who have relapsed after anti-CD19 CAR-T therapy or are ineligible for CAR-T treatment. The company is also advancing MT-401 in AML/MDS, including an off-the-shelf program direction, while historically exploring pancreatic cancer and other solid-tumor applications. Recent company disclosures suggest that the near-term clinical narrative is increasingly concentrated on MT-601 and on building evidence in blood-cancer indications where unmet need remains high.([markertherapeutics.com](https://markertherapeutics.com/?utm_source=openai)) In competitive terms, Marker sits in a crowded and technically demanding cell-therapy landscape alongside CAR-T and TCR-based developers. Its differentiation lies in a multi-antigen, non-genetically modified T-cell platform that may offer a distinct safety/efficacy profile, especially in relapsed or refractory disease settings. However, the company remains a small-cap development-stage player competing against much better capitalized incumbents with approved therapies and broader commercial infrastructure. As a result, investor attention tends to focus on clinical durability, manufacturing scalability, and access to non-dilutive or equity capital.([markertherapeutics.com](https://markertherapeutics.com/our-company/overview/?utm_source=openai)) Recent milestones include encouraging clinical updates for MT-601 in lymphoma, continued progression of the MT-401 RAPID study, and multiple non-dilutive funding awards from U.S. public institutions such as the NIH, CPRIT, and other agencies supporting development programs. In 2025–2026, Marker also highlighted scientific presentations and operational updates, while separately increasing its authorized share count in 2026, a move that can improve financing flexibility for a biotech still in development mode. Overall, MRKR remains a Nasdaq-listed, Houston-based U.S. biotech story centered on early clinical proof-of-concept and platform validation rather than near-term profitability.([ir.markertherapeutics.com](https://ir.markertherapeutics.com/news-releases/news-release-details/marker-therapeutics-reports-third-quarter-2025-financial-results?utm_source=openai))